Head to head
Ecnoglutide against Semaglutide
A long-acting GLP-1 agonist approved in China in 2026 against the GLP-1 agonist that defined the class. Both are weekly injections; what differs is where each is approved and how much trial evidence sits behind each.
Column A
EcnoglutideEcnoglutide (long-acting GLP-1 agonist)
A long-acting GLP-1 agonist in Phase 3 development, notable for the potential of extended, less frequent dosing.
Column B
SemaglutideSemaglutide (GLP-1 receptor agonist)
A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with proven cardiovascular risk reduction.
Side by side, on the facts we can check
| Attribute | Ecnoglutide | Semaglutide |
|---|---|---|
| Category | Metabolic | Metabolic |
| FDA status | Not FDA-approved; approved in China (NMPA) in January 2026 for type 2 diabetes and March 2026 for chronic weight management | FDA-approved (Ozempic, Rybelsus for T2D; Wegovy injection, Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management) |
| Half-life | Long-acting | ~7 days |
| Molecular weight | 4,285 Da | 4,113.6 Da |
| Mechanism | Activates the GLP-1 receptor with an extended half-life to improve glucose control and reduce appetite. | Activates the GLP-1 receptor, increasing insulin secretion when glucose is elevated, suppressing glucagon, slowing gastric emptying, and acting on hypothalamic appetite centers to reduce food intake. |
| Human studies cited | 3 | 5 |
| Legal status, US | Investigational, not approved | FDA-approved, prescription only |
Frequently asked questions
What is the difference between Ecnoglutide and Semaglutide?
Ecnoglutide: A long-acting GLP-1 agonist in Phase 3 development, notable for the potential of extended, less frequent dosing. Semaglutide: A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with proven cardiovascular risk reduction.
Which has stronger research evidence, Ecnoglutide or Semaglutide?
This database does not grade compounds. It counts what was run in people: 3 of the 4 studies cited on the Ecnoglutide profile were human work, against 5 of 5 for Semaglutide. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Ecnoglutide and Semaglutide FDA-approved?
Ecnoglutide: Not FDA-approved; approved in China (NMPA) in January 2026 for type 2 diabetes and March 2026 for chronic weight management. Semaglutide: FDA-approved (Ozempic, Rybelsus for T2D; Wegovy injection, Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management).
Related posts
Blog articles that cover Ecnoglutide or Semaglutide, newest first.
- Dispatch / Sep 12, 2026 / 8 minDispatch 001: Five Retatrutide Phase 3 Trials Have Finished And None Has Posted Results
- Metabolic / Sep 8, 2026 / 8 minTesofensine Is Not a Peptide: What It Is, the Trials, and the Heart-Rate Issue
- Longevity / Sep 8, 2026 / 12 minPeptides for Longevity: What the Evidence Actually Shows in 2026
- Metabolic / Sep 8, 2026 / 10 minOral GLP-1s in 2026: Wegovy Pill vs Foundayo (Orforglipron) vs Rybelsus, and What Is Coming
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.